TY - JOUR
T1 - Long-term safety of medical cannabis in Parkinson's disease
T2 - A retrospective case-control study
AU - Goldberg, Tomer
AU - Redlich, Yonatan
AU - Yogev, David
AU - Fay-Karmon, Tsvia
AU - Hassin-Baer, Sharon
AU - Anis, Saar
N1 - Publisher Copyright:
© 2023 Elsevier Ltd
PY - 2023/7
Y1 - 2023/7
N2 - Background: Whole-plant medical cannabis (MC) products are widely used for controlling symptoms associated with Parkinson's disease (PD). Despite its widespread use, few studies have investigated the long-term impact of MC on the progression of PD or its safety profile. This study examined the effects of MC on PD in a real-life setting. Methods: A retrospective case-control study of 152 idiopathic PD patients (mean age 69.1 ± 9.0 years), followed at the Sheba Medical Center Movement Disorders Institute (SMDI) from 2008 to 2022 was conducted. Seventy-six patients who used licensed whole-plant medical cannabis (MC) for at least a year were compared to a matched group who did not receive MC in terms of their Levodopa Equivalent Daily Dose (LEDD), Hoehn and Yahr (H&Y) stage, and cognitive, depressive, and psychotic symptoms. Results: The median monthly dose of MC was 20 g (IQR: 20–30), with a median Tetrahydrocannabinol (THC) percentage of 10 (IQR: 9.5–14.15) and a median Cannabidiol (CBD) percentage of 4 (IQR: 2–10). There were no significant differences between the MC and the control groups for LEDD or H&Y stage progression (p = 0.90, 0.77, respectively). A Kaplan-Meier analysis showed no evidence of relative worsening of psychotic, depressive, or cognitive symptoms reported by patients to their treating physicians over time in the MC group (p = 0.16–0.50). Conclusion: Over the 1–3 years of follow-ups, the MC treatment regimens appeared to be safe. MC did not exacerbate neuropsychiatric symptoms and had no detrimental effects on disease progression.
AB - Background: Whole-plant medical cannabis (MC) products are widely used for controlling symptoms associated with Parkinson's disease (PD). Despite its widespread use, few studies have investigated the long-term impact of MC on the progression of PD or its safety profile. This study examined the effects of MC on PD in a real-life setting. Methods: A retrospective case-control study of 152 idiopathic PD patients (mean age 69.1 ± 9.0 years), followed at the Sheba Medical Center Movement Disorders Institute (SMDI) from 2008 to 2022 was conducted. Seventy-six patients who used licensed whole-plant medical cannabis (MC) for at least a year were compared to a matched group who did not receive MC in terms of their Levodopa Equivalent Daily Dose (LEDD), Hoehn and Yahr (H&Y) stage, and cognitive, depressive, and psychotic symptoms. Results: The median monthly dose of MC was 20 g (IQR: 20–30), with a median Tetrahydrocannabinol (THC) percentage of 10 (IQR: 9.5–14.15) and a median Cannabidiol (CBD) percentage of 4 (IQR: 2–10). There were no significant differences between the MC and the control groups for LEDD or H&Y stage progression (p = 0.90, 0.77, respectively). A Kaplan-Meier analysis showed no evidence of relative worsening of psychotic, depressive, or cognitive symptoms reported by patients to their treating physicians over time in the MC group (p = 0.16–0.50). Conclusion: Over the 1–3 years of follow-ups, the MC treatment regimens appeared to be safe. MC did not exacerbate neuropsychiatric symptoms and had no detrimental effects on disease progression.
KW - Adverse events
KW - Cannabinoids
KW - Cannabis safety
KW - Idiopathic Parkinson's disease
UR - http://www.scopus.com/inward/record.url?scp=85159903481&partnerID=8YFLogxK
U2 - 10.1016/j.parkreldis.2023.105406
DO - 10.1016/j.parkreldis.2023.105406
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 37211456
AN - SCOPUS:85159903481
SN - 1353-8020
VL - 112
JO - Parkinsonism and Related Disorders
JF - Parkinsonism and Related Disorders
M1 - 105406
ER -